Streetbeat News

Price Targets

FBP

Keefe, Bruyette & Woods analyst Kelly Motta has maintained an Outperform rating on First BanCorp (NYSE:FBP) and increased the price target from $18.5 to $19.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 2:14 pm

YPF

Citigroup analyst Andres Cardona has upgraded YPF (NYSE:YPF) from Neutral to Buy and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 2:14 pm

LAZR

Goldman Sachs analyst Mark Delaney has reiterated a Sell rating on Luminar Technologies (NASDAQ:LAZR) and reduced the price target from $3 to $2.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 2:12 pm

LRCX

Goldman Sachs analyst Toshiya Hari has reaffirmed a Buy rating on Lam Research (NASDAQ:LRCX) and increased the price target from $700 to $912, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 2:12 pm

INO

Oppenheimer analyst Hartaj Singh has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from Perform to Outperform and set a price target of $4. This upgrade reflects a positive outlook on the company's stock by the analyst.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 2:12 pm

INVZ

Goldman Sachs analyst Mark Delaney has maintained a Buy rating on Innoviz Technologies (NASDAQ:INVZ) but has reduced the price target from $3 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 2:10 pm

COLB

Keefe, Bruyette & Woods analyst Christopher Mcgratty has maintained a 'Market Perform' rating on Columbia Banking System (NASDAQ:COLB) but lowered the price target from $30 to $25.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 2:10 pm

TAL

JP Morgan analyst DS Kim has upgraded TAL Education (NYSE:TAL) from Neutral to Overweight and set a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 2:09 pm

IDYA

Goldman Sachs analyst Corinne Jenkins has reaffirmed a Buy rating on IDEAYA Biosciences (NASDAQ:IDYA) and increased the price target from $36 to $53, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 2:09 pm

FULC

Goldman Sachs analyst Madhu Kumar has maintained a Neutral rating on Fulcrum Therapeutics (NASDAQ: FULC) and increased the price target from $5 to $6.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 2:08 pm